Everything tagged "nasdaq" across the TickerSpark archives.
SK hynix Inc. American Depository Shares When Issued is expected to list on NASDAQ on 2026-07-10, but the price range has not been disclosed. The setup is all about whether investors keep rewarding AI memory leadership or start focusing on cyclicality and geopolitics.
WisdomTree Space Economy Fund is expected to list on NASDAQ on 2026-07-09, but the price range has not been disclosed. The setup is simple: a thematic space-economy basket with early traction, but investors still need to watch how much demand shows up for a niche ETF launch.
Capstone Energy+ (NASDAQ: CEPL) is expected to list on July 8, 2026, but the company has not disclosed a price range yet. This is an uplisting from OTCQX rather than a traditional new-issue IPO, so the key question is how investors weigh real revenue growth against early AI data center execution risk.
BIO-key International, Inc. (NASDAQ: BKYI) is expected to list on 2026-07-08, but the company has not disclosed a price range. This is a resale registration, not a primary capital raise, so the key question is whether the large share block creates pressure or liquidity. Bull case: recurring IAM demand and biometric differentiation; bear case: losses, dilution risk, and a very small cash base.
Capstone Energy Plus, Inc. Common Stock (NASDAQ: CEPL) is expected to list on 2026-07-08, but the price range has not been disclosed. This is not a classic new-money IPO; the current filing is a resale registration, and the company will not receive proceeds from those shares. The setup favors investors who want a turnaround-and-growth story, but the resale overhang and debt load are the key things to watch.
SK Hynix Inc. American Depositary Shares is expected to list on NASDAQ on 2026-07-10, but the price range has not been disclosed. The offering is still in the pre-pricing stage, so the main question is how much investors will pay for a memory leader tied to AI demand. Bull case: record FY2025 results and HBM exposure. Bear case: memory pricing and capital intensity can turn quickly.
Eos Energy Enterprises Inc. Rt is expected to list on NASDAQ on 2026-07-06, but the price range has not been disclosed. The company is already public under EOSE, so this looks more like a rights offering and capital-markets event than a true IPO. The bull case is long-duration storage demand; the bear case is heavy losses, financing needs, and dilution risk.
Alopexx, Inc. (ALPX) is expected to list on NASDAQ on 2026-07-07, but the company has not disclosed a price range or share count yet. The setup is a binary biotech story: broad anti-infective science with a small cash base, but a long path to pivotal data and more capital.
Iron Dome Acquisition I Corp. Class A Ordinary Shares (NASDAQ: IDAC) is expected to list on 2026-07-06, but the price range has not been disclosed. This is a SPAC, so the real question is whether the sponsor can find a credible target in cybersecurity, defense tech, AI, or data infrastructure. The setup favors investors who want exposure to that theme, but the main watch item is whether the deal terms and target pipeline justify the trust-account structure.
Eos Energy Enterprises, Inc. Right is expected to list on NASDAQ on 2026-07-06, but the price range has not been disclosed. The company is already public under NASDAQ: EOSE, so this is best viewed as a capital-markets event rather than a first-time IPO. Bull case: long-duration storage demand is real; bear case: the business is still loss-making and heavily dependent on financing.
IQM Quantum Computers Oyj American Depositary Shares is expected to list on NASDAQ on 2026-07-02, but the price range has not been disclosed. The deal is a SPAC merger with Real Asset Acquisition Corp. under ticker IQMX. Bull case: a real systems-delivery track record; bear case: quantum remains early, loss-making, and execution-heavy.
Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime